Diagnostic confusion resulting from CD56 expression by cutaneous myeloid sarcoma by Ho, Thanh et al.
[page 156] [Rare Tumors 2009; 1:e51]
Rare Tumors 2009; volume 1:exxxx
Diagnostic confusion resulting
from CD56 expression by 
cutaneous myeloid sarcoma 
Thanh Ho,
1 Franklin Sedarat,
1
Nagesh Rao,
2 Sheeja T. Pullarkat,
1
1Department of Pathology and
Laboratory Medicine and 
2Department of
Cytogenetics, David Geffen School of
Medicine, University of California Los
Angeles, Los Angeles, California, USA 
Abstract 
Myeloid sarcomas are tumor masses com-
posed of aggregates of malignant myeloid pre-
cursors in extramedullary sites including the
skin. We report a case of myeloid sarcoma in a
patient who presented with an ear lobe mass
and facial nerve paralysis. Expression of CD56
by the malignant cells led to an initial misdiag-
nosis  as  Merkel  cell  tumor.  Comprehensive
pathological evaluation confirmed the diagno-
sis of myeloid sarcoma with aberrant expres-
sion of CD56 and carrying the translocation
t(8;21) (q22;q22). Aberrant antigen expression
by  cutaneous  myeloid  sarcomas  can  cause
diagnostic  confusion  with  other  cutaneous
neoplasms.  This  is  especially  relevant  when
myeloid sarcoma is the sole manifestation of
acute myeloid leukemia.
Introduction
Certain  hematopoietic  neoplasms  have  a
tendency to involve the skin. Of these the most
common are CD4+/CD56+ hematodermic neo-
plasms  (previously  termed  blastic  natural
killer (NK) cell lymphoma), myeloid sarcomas,
nasal-type extranodal natural killer/T-cell lym-
phoma, and cutaneous T-cell lymphomas.
1 The
term myeloid sarcoma refers to tumors com-
posed  of  aggregates  of  immature  leukemic
myeloid  precursors  in  extramedullary  sites.
2
Myeloid  sarcomas  with  the  chromosomal
translocation t(8;21) frequently express non-
myeloid  antigens  including  CD2,  CD19,  and
CD56. Myeloid sarcomas involving the skin are
a frequent cause of misdiagnosis when they
express  aberrant  non-myeloid  antigens  and
when the underlying leukemia is not overt. We
report a case of CD56-expressing myeloid sar-
coma  that  was  misdiagnosed  as  Merkel  cell
carcinoma,  and  discuss  the  diagnostic
approach toward CD56 expressing cutaneous
tumors.
Case Report 
A 61-year-old woman presented to her physi-
cian with a left ear lobe skin nodule, left facial
nerve palsy, and deafness. Biopsy of the ear
lobe lesion was interpreted initially as Merkel
cell carcinoma. She was referred to our institu-
tion for further evaluation and treatment. Her
past history was relevant for acute myeloge-
nous  leukemia  (AML)  for  which  she  had
received chemotherapy and was in remission.
Imaging studies performed in our institution
showed a soft tissue mass involving the left
mastoid space and extending into the posteri-
or middle cranial fossa. In addition a paraver-
tebral mass extending from the third to sixth
thoracic vertebra was noted.  
The biopsy specimen from the ear lobe mass
was received for consultation from the refer-
ring hospital and revealed a diffuse prolifera-
tion of atypical mononuclear cells within the
dermis with an intact epidermis (Figure 1A).
These  cells  were  medium  to  large  and  had
moderate  amounts  of  cytoplasm,  irregular
nuclear  contours,  and  finely  dispersed  chro-
matin  (Figure  1B).  Immunohistochemical
stains  showed  the  tumor  cells  to  express
myeloperoxidase (MPO) (Figure 1C). In addi-
tion  they  were  positive  for  CD45  (leukocyte
common  antigen),  CD43,  CD117,  CD34
(Figure 1D), and CD56 (Figure 1E). They were
negative  for  CD20  and  CD3.  A  diagnosis  of
myeloid sarcoma was made. Fluorescent in situ
hybridization (FISH) studies were performed
on  the  skin  lesion  using  dual-color  DNA
probes:  Spectrum  Orange-labeled  LSI
RUNX1T1 (8q22) probe and Spectrum Green-
labeled LSI RUNX1 (21q22) probe to identify
the  t(8;21)  fusion  signals  (Abbot  Mol-
ecular/Vysis, Des Plaines, IL).
3 The cells ana-
lyzed were positive for the reciprocal transloca-
tion t(8;21)(q22;q22) (Figure 1F). 
A concurrent bone marrow biopsy showed a
hypercellular bone marrow involved by acute
myelogenous leukemia with t(8;21)(q22;q22).
She  received  myeloablative  conditioning
chemotherapy and an allogeneic hematopoiet-
ic  stem  cell  transplant,  following  which  she
developed  persistent  pancytopenia  and  died
from sepsis.
Discussion
Our case highlights a pitfall in the diagnosis
of cutaneous myeloid sarcomas that express
CD56, a non-myeloid antigen. CD56 or neural
cell adhesion molecule (NCAM) is a cell mem-
brane protein involved in adhesion of neural
cells. CD56 is expressed on NK cells, on a sub-
set  of  peripheral  CD8
+ T-cells,  on  neural  or
neuroendocrine cells, and on peripheral blood
monocytes.
4,5 Hematopoietic  and  non-hema-
topoetic  neoplasms  that  express  CD56  can
involve the skin. Cutaneous non-hematopoiet-
ic  tumors  that  are  CD56  positive  include
Merkel cell carcinomas and metastases to the
skin from other primary neuroendocrine carci-
nomas. Merkel cell carcinomas present as der-
mal  nodules  mainly  involving  the  head  and
neck  regions,  with  a  characteristic  salt-and-
pepper nuclear chromatin histologically.
6-8 The
tumors are CD45 negative and stain for cytok-
eratin  20  (CK20),  CAM  5.2,  and  CD56.
Metastatic neuroendocrine tumors to the skin
have an immunophenotype similar to the pri-
mary tumor and frequently express CD56.
A  review  of  CD56  positive  hematological
neoplasms presenting in the skin, conducted
by the Cutaneous Lymphoma Task Force of the
European  Organisation  for  Research  and
Treatment of Cancer,
1recognizes four different
subtypes of proliferations with CD56 expres-
sion:  (i)  CD4
+/CD56
+ hematodermic  neo-
plasms (previously designated as blastic NK-
cell lymphomas); (ii) skin infiltration by CD56
positive acute myelogenous leukemia (myeloid
sarcoma); (iii) nasal-type extranodal NK/T cell
lymphomas; and (iv) “classical” cases of cuta-
neous T-cell lymphoma (CTCL) with coexpres-
sion of the CD56 molecule.  
CD4 and CD56 positive hematodermic neo-
plasm is a recently recognized entity that orig-
inates  from  plasmacytoid  dendritic  cells
(pDC), has a high incidence of skin involve-
ment and leukemic dissemination, an aggres-
sive clinical course, and a dismal prognosis.
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Extranodal NK/T cell lymphoma most common-
ly occurs in the nasopharngeal area and fre-
quently shows an angiocentric growth pattern
with  prominent  necrosis,  and  once  was
referred to as lethal midline granuloma. Most
cases are associated with Epstein Barr Virus
(EBV) and express cytotoxic molecules such as
perforin, granzyme B, and TIA-1. Occasionally,
CD56 may be expressed also by cutaneous T-
cell  lymphoma  such  as  primary  cutaneous
CD30
+ lymphoproliferations,  anaplastic  large
cell  lymphomas  (ALCL),  and  subcutaneous
panniculitis-like  T-cell  lymphomas.  Results
from this study showed that CD56
+ cutaneous
lymphoproliferative disorders, with the excep-
tion of CD56
+ CTCL, have a very poor progno-
sis. 
Previous reports have highlighted the diffi-
culty  in  the  diagnosis  of  cutaneous  myeloid
sarcomas owing to the aberrant expression of
lymphoid  antigens.  Kurata  et  al.
10 have
described a case of a 39-year-old man who pre-
sented with a forehead cutaneous nodule that
was positive for CD45 and CD56, and negative
for CD3, CD20, CD34, TIA-1, and TdT. Only a
limited panel of immunostains was performed,
hence leading to a misdiagnosis of NK cell lym-
phoma. The initial biopsy specimen when re-
evaluated showed expression of myeloid anti-
gens, namely myeloperoxidase (MPO), and the
diagnosis of myeloid sarcoma was made final-
ly. Beswick et al.
11 described a case of a 65-
year-old man who presented with a nodule on
the back that was diagnosed as high-grade T-
cell lymphoma by virtue of CD3 expression. He
received chemotherapy and three years later
developed violaceous nodules over his trunk
and limbs. Biopsy of this mass and a detailed
immunohistochemistry  panel  revealed  a
myeloid sarcoma that was positive for CD45,
CD43, CD4, CD31, and chloroacetate esterase.
The initial biopsy was reviewed and was found
to be a myeloid sarcoma and not a T-cell lym-
phoma.
A recent report by Pileri et al. reviewing 92
cases  of  myeloid  sarcomas  in  adults  has
heightened our knowledge on myeloid sarco-
mas. They have illustrated that the tumor cells
in  myeloid  sarcomas  most  commonly
expressed  CD68/KP1  (100%),  followed  in
decreasing order by myeloperoxidase (83.6%),
CD117  (80.4%),  CD99  (54.3%),  CD68/PG-M1
(51%),  CD34  (43.4%),  CD56  (13%),  CD61
(2.2%), CD30 (2.2%), and glycophorin A and
CD4 (1.1%).
12 Chromosomal abberations were
detected in about 54% of cases and monosomy
7 (10.8%), trisomy 8 (10.4%), and mixed line-
age leukemia-splitting (8.5%) were the com-
monest abnormality. 
Since detection of genetic lesions is critical
for classification, prognostic stratification, and
monitoring of AML, it is very important that
FISH studies on the paraffin-embedded tissue
for chromosomal abnormalities, namely mono-
somy 7, trisomy 8, 11q23 rearrangement, and
t(8;21), are performed to aid in further prog-
nostication when myeloid sarcoma is the sole
manifestation of acute myeloid leukemia. This
is mainly owing to the fact that since the diag-
nosis of myeloid sarcoma frequently is unex-
pected, fresh cells are not available usually for
cytogenetic and/or molecular studies. 
In  summary,  myeloid  sarcoma  should  be
considered  in  the  differential  diagnosis  of
cutaneous CD56 positive tumors that are CD45
positive and lack expression of cytokeratin and
other neural markers. 
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